Home > Healthcare > Pharmaceuticals > Pharma Manufacturing > Oral Solid Dosage Contract Manufacturing Market

Oral Solid Dosage Contract Manufacturing Market Trends

Report ID: GMI9169
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Oral Solid Dosage Contract Manufacturing Market Trends

Growing number of strategic partnerships between pharmaceutical companies and CDMOs is a significant driver of the market.
For instance, in June 2022, Pierre Fabre, a French pharmaceutical group, entered into a manufacturing agreement with Lonza. This helped the company to leverage Lonza's drug product expertise and fill and finish capabilities Similarly, in January 2023, Context Therapeutics and Lonza entered into a manufacturing agreement for the development and manufacturing of a bispecific antibody clinical candidate. Such growing number of partnerships aid in the market growth.
These partnerships enable pharmaceutical companies to leverage the specialized capabilities and expertise of CDMOs in oral solid dosage manufacturing, including formulation development, scale-up, and commercial production.
Further, by collaborating with CDMOs, pharmaceutical companies can accelerate the development and commercialization of new products, optimize manufacturing processes, and access a broader range of manufacturing technologies and facilities.
Thus, as more companies partner with CDMOs, the market is anticipated to witness lucrative growth over the analysis period.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Oral solid dosage contract manufacturing market size was USD 35.6 billion in 2023 and is expected to register 5.6% CAGR from 2024-2032 owing to the rising trend of outsourcing manufacturing by pharmaceutical companies worldwide.

Oral solid dosage contract manufacturing industry from the tablets segment reached USD 11.6 billion in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to their convenience, ease of administration, and patient compliance.

North America oral solid dosage contract manufacturing industry is expected to register 5.3% CAGR from 2024-2032 due to advanced healthcare infrastructure, stringent regulatory framework, and the presence of prominent pharmaceutical companies in the region.

Aenova Group, Catalent, Inc., Corden Pharma International, Jubilant Pharmova Limited, Lonza, NextPharma Technologies, Patheon Pharma Services (Thermo Fisher Scientific Inc.), and Siegfried Holding AG, are some of the major oral solid dosage contract manufacturing companies worldwide.